AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22154896
Drug: SODAS dexmethylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SODAS dexmethylphenidate 40 mg
Trial: 22154896
Drug: SODAS dexmethylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SODAS dexmethylphenidate (all doses)
Trial: 22155140
Drug: Etanercept (Enbrel®,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (Enbrel®, Amgen Inc.) 0.4 mg/kg/dose, subcutaneously, twice weekly, for 4 weeks (group A) or 12 weeks (group B)
Trial: 22155453
Drug: Monoclonal antibody
RxNorm normalized name: Monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody 9E18 targeting GPVI dimers
Trial: 22155453
Drug: ADP receptor
RxNorm normalized name: ADP-597
DrugBank: ADP-597 (DB12084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADP receptor P2Y12 antagonists
Trial: 22156656
Drug: Metronomic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic chemotherapy regimen (vinblastine 3 mg/m2 weekly for 7 weeks, cyclophosphamide 30 mg/m2 daily for 21 days, methotrexate 10 mg/m² twice weekly for 3 weeks, celecoxib 100 mg to 400 mg twice daily for 56 days)
Trial: 22156656
Drug: Metronomic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic chemotherapy regimen
Trial: 22157574
Drug: Topical immunosuppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical immunosuppression with cyclosporine
Trial: 22158386
Drug: Treosulfan (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treosulfan (3 × 14 g/m²) and Fludarabine (5 × 30 mg/m²)
Trial: 22160069
Drug: Regular blood
RxNorm normalized name: Irregular blood group antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular blood transfusion therapy
Trial: 22160298
Drug: Enzastaurin 500
RxNorm normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzastaurin 500 mg daily and Erlotinib 150 mg daily
Trial: 22160384
Drug: Anti-CD19-CAR-transduced T
RxNorm normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-CD19-CAR-transduced T cells infusion after chemotherapy and IL-2 course
Trial: 22160384
Drug: Anti-CD19-CAR-transduced T
RxNorm normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-CD19-CAR-transduced T cells infusion
Trial: 22165955
Drug: DAB/IL2 (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAB/IL2 (12 μg/kg; 4 daily doses; 21 day cycles)
Trial: 22169779
Drug: Peg-IFN-α for
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peg-IFN-α for 9 months before and for 3 months following IM discontinuation
Trial: 22169779
Drug: Peg-IFN-α therapy
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peg-IFN-α therapy
Trial: 22169779
Drug: Patients off
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients off IM therapy
Trial: 22170360
Drug: Red meat
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red meat intake (62.7 g per 1000 kcal in quintile 5)
Trial: 22170723
Drug: Metreleptin replacement
RxNorm normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metreleptin replacement therapy (0.08 mg/kg·d by twice daily sc injections for 6 months) in SH group
Trial: 22170723
Drug: Metreleptin replacement
RxNorm normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metreleptin replacement therapy (0.08 mg/kg·d by twice daily sc injections for 6 months) in MH group
Trial: 22170723
Drug: Metreleptin replacement
RxNorm normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metreleptin replacement therapy in SH group
Trial: 22170723
Drug: Metreleptin replacement
RxNorm normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metreleptin replacement therapy in MH group
Trial: 22171692
Drug: Metformin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin treatment (in both sets)
Trial: 22171697
Drug: Neoadjuvant chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoradiation therapy (25 fractions of 2 Gy with concurrent capecitabine) followed by Transanal Endoscopic Microsurgery (TEM)
Trial: 22172590
Drug: 8-h nocturnal
RxNorm normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 8-h nocturnal in-center thrice weekly hemodialysis (NHD)
Trial: 22172590
Drug: 4-h thrice
RxNorm normalized name: Thrive 4 MG Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-h thrice weekly conventional hemodialysis (CHD)
Trial: 22173060
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m² intravenously once a week for 4 weeks) followed by CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone every 3 weeks for 4 cycles)
Trial: 22176583
Drug: Sit-to-stand activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sit-to-stand activity prompted by health care aides (twice daily during care routines)
Trial: 22176869
Drug: Sunitinib 37.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5mg once daily continuously with 4-week cycle
Trial: 22177085
Drug: High cereal-fiber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High cereal-fiber diet (HCF, 43 g/day)
Trial: 22177085
Drug: High-protein diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein diet (HP, 28% of energy-intake, cereal-fiber 14 g/day)
Trial: 22177085
Drug: Moderately high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately high cereal fiber/protein diet (MIX, protein 23% of energy-intake, cereal-fiber 26 g/day)
Trial: 22177085
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (cereal-fiber 14 g/day)
Trial: 22178121
Drug: Bevacizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (15 mg/kg) and cisplatin (100 mg/m(2)) on days 1, 22, and 43 of radiation (70 Gy) with intensity-modulated radiation therapy over 33 days, followed by bevacizumab (15 mg/kg) and cisplatin (80 mg/m(2)) on days 64, 85, and 106 after radiation, and fluorouracil (1000 mg/m(2) per day) on days 64-67, 85-88, and 106-109 after radiation.
Trial: 22179536
Drug: Collagenase therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagenase therapy (300 to 1200 μg) delivered locally into occlusions via over-the-wire balloon system or fine-cross microcatheter for 30 minutes.
Trial: 22179536
Drug: Collagenase therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagenase therapy (300 to 1200 μg) delivered locally into occlusions.
Trial: 22180427
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of deferiprone and desferrioxamine
Trial: 22182397
Drug: NGX-4010 (capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGX-4010 (capsaicin 8% dermal patch) after pretreatment with lidocaine 2.5%/prilocaine 2.5% cream
Trial: 22182397
Drug: NGX-4010 (capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGX-4010 (capsaicin 8% dermal patch)
Trial: 22185672
Drug: Artemether-lumefantrine (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine (standard treatment)
Trial: 22185681
Drug: Epidural injection
RxNorm normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injection of 80 mg acetate methylprednisolone
Trial: 22185681
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of 80 mg acetate methylprednisolone
Trial: 22185733
Drug: Decongestion (0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decongestion (0.05% oxymetazoline chloride applied as an aerosol spray)
Trial: 22186627
Drug: Bortezomib (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib (1.5 mg/m2) administered twice a week for 2 consecutive weeks (days 1, 4, 8, and 11) followed by a 10-day rest period.
Trial: 22186627
Drug: Bortezomib (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib (1.5 mg/m2) administered as described above.
Trial: 22189340
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g ertapenem
Trial: 22190606
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of etravirine/12 h (Control)
Trial: 22190606
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of etravirine/24 h (Intervention)
Trial: 22197613
Drug: Vatalanib 1250
RxNorm normalized name: Vatalanib
DrugBank: Vatalanib (DB04879)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vatalanib 1250 mg orally once daily
Trial: 22198152
Drug: EX-527 (SIRT1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EX-527 (SIRT1 inhibitor)
Trial: 22198412
Drug: Lapatinib (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (1,500 mg oral daily) plus Bevacizumab (10 mg/kg IV every 2 weeks)
Trial: 22202188
Drug: Transcranial magnetic
RxNorm normalized name: transcranial magnetic stimulator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial magnetic stimulation (TMS) followed by speech therapy (constraint-induced language therapy)
Trial: 22203761
Drug: Subcutaneous GM-CSF
RxNorm normalized name: axatilimab-csfr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous GM-CSF during cycle 1 and intravenous GM-CSF during cycle 4
Trial: 22203761
Drug: Subcutaneous GM-CSF
RxNorm normalized name: axatilimab-csfr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous GM-CSF at both cycles
Trial: 22203761
Drug: Anti-GD2 monoclonal
RxNorm normalized name: Anti-GD2 monoclonal antibody 3F8
DrugBank: Anti-GD2 monoclonal antibody 3F8 (DB15388)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-GD2 monoclonal antibody and GM-CSF
Trial: 22203761
Drug: Second-line cyclophosphamide-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line cyclophosphamide-based therapy before protocol entry
Trial: 22206473
Drug: Endogenously released
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endogenously released glucose, insulin, GLP-1, ghrelin
Trial: 22206473
Drug: Insulin 0-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin 0-30 min AUC
Trial: 22206581
Drug: 17-hydroxyprogesterone caproate
RxNorm normalized name: 6α-Methyl-17α-hydroxyprogesterone acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17-hydroxyprogesterone caproate (17P) 250 mg in 1 mL castor oil, weekly intramuscular injection
Trial: 22206581
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 mL castor oil), weekly intramuscular injection
Trial: 22210091
Drug: Panitumumab at
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab at 6 mg/kg every 14 days (cycle length = 28 days)
Trial: 22212936
Drug: Sorafenib administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib administration after curative treatment (resection or ablation)
Trial: 22212936
Drug: Pegylated interferon-α2a
RxNorm normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon-α2a long-term maintenance therapy
Trial: 22215271
Drug: Office-based buprenorphine-naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Office-based buprenorphine-naloxone treatment
Trial: 22215271
Drug: Office-based buprenorphine-naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Office-based buprenorphine-naloxone treatment with 50% price reduction
Trial: 22215271
Drug: Office-based buprenorphine-naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Office-based buprenorphine-naloxone treatment with alternative quality-of-life weights
Trial: 22217879
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of cardioprotective drugs for 1 month or more
Trial: 22218721
Drug: Weekly low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly low-dose (25,000 IU) vitamin A
Trial: 22218909
Drug: Gemcitabine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine at 1,000 mg/m(2) and oxaliplatin at 100 mg/m(2) every 2 weeks
Trial: 22223235
Drug: tPA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tPA plus Argatroban (100-μg/kg bolus and infusion for 48 hours)
Trial: 22223821
Drug: rFVIIIFc (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFVIIIFc (recombinant factor VIII Fc fusion protein) at doses of 25 or 65 IU/kg
Trial: 22225488
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiotherapy (SBRT) with 1, 3, or 5 fractions for median doses of 18, 27, and 30 Gy respectively.
Trial: 22225857
Drug: 30mg of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg of pioglitazone after 81mg of aspirin
Trial: 22228449
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg/day for 4 weeks followed by 2 weeks of rest
Trial: 22228827
Drug: Telephone-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based cognitive-behavioral therapy (CBT) for depression in Parkinson disease, provided for 10 weeks, supplemented with 4 phone-based caregiver educational sessions.
Trial: 22231150
Drug: Parenteral opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral opioid analgesia (morphine or hydromorphone) via patient-controlled analgesia (PCA)
Trial: 22232031
Drug: Intrathecal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal administration of cultured autologous bone marrow stromal cells (BMSCs)
Trial: 22232483
Drug: β-Blocking treatment
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-Blocking treatment
Trial: 22232483
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no β-Blocking treatment)
Trial: 22233617
Drug: Treatment according
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment according to European guidelines on cardiovascular disease prevention
Trial: 25896390
Drug: Stem Cell
RxNorm normalized name: Stem cells, apheresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stem Cell Educator therapy
Trial: 22234716
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy (most preferred CAM option)
Trial: 22235096
Drug: OXi4503 (combretastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXi4503 (combretastatin A1 diphosphate, CA1P) administered intravenously at escalating doses from 0.06 to 1.92 mg/m(2), then expanded cohorts to 15.4 mg/m(2) on days 1, 8, and 15 every 28 days.
Trial: 22235096
Drug: Maximum tolerated
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum tolerated dose of OXi4503 was 8.5 mg/m(2), escalation to 14 mg/m(2) was possible with temporary reversible cerebrovascular toxicity.
Trial: 22235243
Drug: Weekly 135
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly 135 µg peginterferon-α 2a plus ribavirin 400 mg twice daily during 20 weeks
Trial: 22236508
Drug: Invasive testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive testing (intracoronary acetylcholine administration, fast atrial pacing)
Trial: 22241828
Drug: QSU-Brief questionnaire
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: QSU-Brief questionnaire administered to Black light smokers
Trial: 22244711
Drug: Antithrombotic medications
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic medications continued
Trial: 22244711
Drug: Antithrombotic medications
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic medications temporarily discontinued
Trial: 22247403
Drug: Hippotherapy (45-minute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hippotherapy (45-minute sessions twice per week for 6 weeks)
Trial: 22248486
Drug: Daily vitamin
RxNorm normalized name: Daily Vitamin Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily vitamin D intake of 400 IU
Trial: 22249106
Drug: Tigecycline 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tigecycline 0.75 mg/kg
Trial: 22249106
Drug: Tigecycline 1
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tigecycline 1 mg/kg
Trial: 22249106
Drug: Tigecycline 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tigecycline 1.25 mg/kg
Trial: 22249106
Drug: Tigecycline 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tigecycline 1.2 mg/kg q12h (predicted)
Trial: 22249430
Drug: Dacomitinib 15
RxNorm normalized name: dacomitinib 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacomitinib 15 mg QD
Trial: 22249430
Drug: Dacomitinib 30
RxNorm normalized name: dacomitinib 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacomitinib 30 mg QD
Trial: 22250979
Drug: Indinavir/ritonavir (IDV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir/ritonavir (IDV/r) 600/100 mg plus lamivudine and stavudine administered every 12 hours (bid)
Trial: 22250979
Drug: Indinavir/ritonavir (IDV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir/ritonavir (IDV/r) treatment
Trial: 22250979
Drug: Indinavir/ritonavir (IDV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir/ritonavir (IDV/r) treatment with concomitant rifampicin
Trial: 22252944
Drug: Association of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Association of body fat with hormone levels
Trial: 22253412
Drug: Synchronous bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Synchronous bevacizumab and erlotinib with concurrent cisplatin and twice daily radiotherapy
Trial: 22258268
Drug: Increased dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increased dietary sodium intake of 1000 mg/d
Trial: 22258268
Drug: Top quintile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Top quintile dietary sodium consumption (>1456 mg/d)
Trial: 22258268
Drug: 1000-mg/d difference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000-mg/d difference in dietary sodium between brothers
Trial: 22258271
Drug: Gluten-free diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gluten-free diet (GFD) with ingestion of <100 mg gluten/d
Trial: 22258545
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor (letrozole 12.5 mg/day for 3 days)
Trial: 22259028
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg daily dose
Trial: 22260199
Drug: Spinal block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal block using 10 mg 0.5% (w/v) bupivacaine
Trial: 22262746
Drug: Everolimus, titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus, titrated to tolerability to achieve target trough concentrations of 5-15 ng/mL
Trial: 22263047
Drug: CP +
RxNorm normalized name: methylcellulose (1500 CPS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP + ASA404 (1200 mg/m(2) or 1800 mg/m(2))
Trial: 22263047
Drug: CP alone
RxNorm normalized name: methylcellulose (1500 CPS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP alone (Carboplatin AUC 6 mg/ml•min and Paclitaxel 175 mg/m(2))
Trial: 22267606
Drug: Low-dose rituximab
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rituximab (100 mg fixed dose for 4 weekly infusions) with a short course of steroids
Trial: 22267607
Drug: Trastuzumab (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab (4 mg/kg intravenous loading dose followed by 2 mg/kg weekly)
Trial: 22267687
Drug: FF/VI 400/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/VI 400/25 μg once daily for 4 weeks
Trial: 22267829
Drug: 25% human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% human albumin at 1.25 g/kg/day for 7 days (Tier 2)
Trial: 22267829
Drug: 25% human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% human albumin at 0.625 g/kg/day for 7 days (Tier 1)
Trial: 22267829
Drug: 25% human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% human albumin at 1.875 g/kg/day for 7 days (Tier 3)